Evidence explainerMenopause & Perimenopause

The FDA Took the Black Box Off Menopause Hormones. Here Is What the Trials Actually Showed

The 2002 Women's Health Initiative scared a generation off hormone therapy. Twenty years of follow-up, a trial on timing and a 2026 label change tell a more careful story, including the risks that remain.

By Kymata Health editorial teamPublished October 10, 2026Last verified October 10, 2026

Medical review pending. Written by our editorial team from the studies and documents cited below; a credentialed clinician has not reviewed it yet. Educational only, not medical advice.

Key takeaways

  • The FDA approved revised labels for six menopausal hormone products on February 12, 2026, removing cardiovascular disease, breast cancer and probable dementia from the boxed warning [1].
  • The boxed warning for endometrial cancer remains on systemic estrogen-alone products, which is why women with a uterus take a progestogen with estrogen [2].
  • Across both WHI trials, 18-year all-cause mortality was 27.1% with hormones vs 27.6% with placebo (HR 0.99) [3].
  • Estrogen plus progestin raised breast cancer incidence over 20 years (HR 1.28); estrogen alone in women without a uterus lowered it (HR 0.78) [4].
  • Timing matters: estradiol slowed artery-wall thickening only when started within 6 years of menopause [5].

What the FDA changed, and what it did not

On November 10, 2025 the FDA asked makers of menopausal hormone therapy to remove the language on cardiovascular disease, breast cancer and probable dementia from the boxed warning, and to add a consideration of starting treatment for moderate to severe hot flashes in women under 60 or within 10 years of menopause [2]. The first six revised labels were approved on February 12, 2026 [1].

The change moves those risks out of the box, not off the label: the warnings section still covers cardiovascular disease and breast cancer, and the endometrial-cancer box stays on systemic estrogen-alone products [2]. The FDA's own reasoning notes that the dementia finding came from WHI participants aged 65 to 79, much older than women who usually start hormones [2].

What the 2002 trial found

The WHI estrogen-plus-progestin trial (conjugated equine estrogens with medroxyprogesterone acetate) stopped after a mean 5.2 years because invasive breast cancer crossed its stopping boundary [6]. Hazard ratios were 1.26 for breast cancer, 1.29 for coronary heart disease, 1.41 for stroke and 2.13 for pulmonary embolism, while hip fractures (0.66) and colorectal cancers (0.63) fell [6].

In absolute terms that was about 7 more coronary events, 8 more strokes, 8 more pulmonary emboli and 8 more invasive breast cancers per 10,000 women per year, against 6 fewer colorectal cancers and 5 fewer hip fractures [6].

Twenty years later

With 18 years of follow-up on 27,347 women, hormone therapy did not change all-cause, cardiovascular or cancer mortality overall [3]. During the treatment years, women who started at 50 to 59 had a lower all-cause mortality hazard relative to women who started at 70 to 79 (ratio of hazard ratios 0.61) [3].

Breast cancer splits by regimen. Over a median of more than 20 years, estrogen plus progestin in women with a uterus raised breast cancer incidence (HR 1.28) without a significant change in breast cancer deaths, while estrogen alone in women who had a hysterectomy lowered both incidence (HR 0.78) and breast cancer deaths (HR 0.60) [4].

The timing question

ELITE randomized 643 healthy postmenopausal women to oral estradiol or placebo, split by time since menopause [5]. Artery-wall thickness (carotid intima-media thickness) progressed more slowly on estradiol in women less than 6 years past menopause, but not in women 10 or more years past it; coronary CT measures did not differ in either group [5].

The 2022 hormone therapy position statement reflects this: for women under 60 or within 10 years of menopause with no contraindications, the benefit-risk balance is favorable for bothersome hot flashes and bone protection, and it is less favorable for women who start later [7].

Who still should not take it

Hormone therapy is not for everyone. A history of breast cancer, blood clots, stroke, heart disease or unexplained vaginal bleeding usually rules out systemic estrogen, and the choice of pill vs patch, dose and progestogen changes the risk [7]. These are decisions for a clinician who knows your history; if hormones are off the table, see our guide to non-hormonal hot flash treatments.

Partners we link to

Paid links: we earn a commission if you buy through these, at no extra cost to you. It never changes what the evidence sections say. Affiliate disclosure.

  • WinonaPaid linkOnline menopause care with FDA-approved estradiol tablets (from $54/mo published, checked Oct 8, 2026) plus compounded creams that are not FDA-approved. Ages 35 to 59; runs its own 503A pharmacies.See Winona's menopause plans
  • GalaPaid linkOnline hormone care for women from a published "from $69/mo" price (checked Oct 8, 2026); Gala says it prescribes FDA-approved bioidentical forms and ships free.See Gala's hormone plans

Quick answers

Did the FDA say hormone therapy is risk-free?

No. It moved cardiovascular, breast cancer and dementia language out of the boxed warning; cardiovascular and breast cancer warnings remain lower in the label, and the endometrial cancer box stays on systemic estrogen-alone products [2].

Is a patch safer than a pill?

The 2022 position statement says risk depends on route as well as type, dose, duration and timing; your clinician weighs route against your own risk factors [7].

Does the WHI apply to me if I am 52?

WHI participants averaged 63, and women who started at 50 to 59 had better mortality ratios than women who started at 70 to 79 [3].

More in Menopause & Perimenopause

References

  1. [1]FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. U.S. Food and Drug Administration, 2026.
  2. [2]FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies. U.S. Food and Drug Administration, 2025.
  3. [3]Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 2017. PMID 28898378
  4. [4]Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA, 2020. PMID 32721007
  5. [5]Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE). N Engl J Med, 2016. PMID 27028912
  6. [6]Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002. PMID 12117397
  7. [7]The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. PMID 35797481

Dietary supplements are not intended to diagnose, treat, cure or prevent any disease, and these statements have not been evaluated by the FDA. Prescription options need a licensed clinician. Talk to your clinician or pharmacist before starting anything new, especially if you take prescription medicines, are pregnant or breastfeeding.

Keep reading: Menopause and HRT

Menopause and HRT: every page →Women's hormone telehealth compared →Browse all topics →

Previous in this topicMenopause and Perimenopause: What the Evidence Says About Hormones, New Non-Hormonal Drugs and SupplementsHormone therapy is still the most effective treatment for hot flashes, the FDA removed most of its boxed warning in 2026, two non-hormonal pills are now approved, and most…Next in this topicCan't or Won't Take Hormones? The Non-Hormonal Hot Flash Treatments That Beat PlaceboTwo new brain-targeted pills, an older list of repurposed drugs, and behavioral therapy all have trial data for hot flashes.Menopause Supplements vs Placebo: Black Cohosh, Soy and the Blends Sold on InstagramBlack cohosh did no better than placebo for hot flashes in pooled trials.Best Peptides for Women Over 40: Menopause, Fat Loss, Sleep & SkinEvidence-based guide to peptides for women over 40 - menopause weight gain, sleep disruption, skin aging, libido, and which peptides address each.Peptides for Women's Health: Hormones, Hair, and HealingWomen-specific peptide protocols are underrepresented in the literature.

Menopause treatment cost →3 a.m. waking in menopause →